20 units of Jeuveau®

every 90 days

$

49

/MO*

/MOnth

Join The Club
Floating only sticker
Save more,
Frown Less
Just $49/Month.

The exclusive Jeuveau® membership designed to maximize savings on frown line treatments*

*Jeuveau® is a prescription injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows in adults.
Join The ClubTerms and Conditions Apply
How It Works Graphic

how it works

Step 1

Sign up by clicking “JOIN THE CLUB” and choose a participating Club Evolus practice near you.

Step 2

You'll be charged $49 every 30 days and will be eligible for your first treatment after 3 payments.

Step 3

Book with your provider to complete your Club Evolus check-in and get treated with 20 units of Jeuveau®. In 90 days, you’ll be eligible for your next club appearance (aka 20 unit treatment).

Can’t wait for your first treatment?  Pre-pay your first three payments to get treated as early as today.

Join The Club
About Jeuveau GraphicAbout Jeuveau Graphic

At Evolus, we stand by the science of visible results. Our signature modern-made tox Jeuveau is a precise product, with a tight field of effect, (temporarily) reducing frown lines in as little as two days for a natural look you’ll love. 10 minutes is all it takes to get treated!

† About 50% of patients begin showing improvement after 2 days. Most patients (~69%) achieve complete results by 30 days.

learn more

Jeuveau® Before + Afters

Day 0 & Day 30
Day 2
Day 30
Day 120
Day 0 & Day 30
Day 2
Day 30
Day 120
Soo Youn
Soo Youn
Soo Youn
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo YounSoo Youn
David
David
David
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
David
David
David
David
David
David
DavidDavid
Arielle
Arielle
Arielle
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
ArielleArielle
Sarah
Sarah
Sarah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
SarahSarah
Tajah
Tajah
Tajah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
TajahTajah
Lisa
Lisa
Lisa
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
LisaLisa
Tia
Tia
Tia
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tia
Tia
Tia
Tia
Tia
Tia
TiaTia
Shai
Shai
Shai
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Shai
Shai
Shai
Shai
Shai
Shai
ShaiShai
Tugba
Tugba
Tugba
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
TugbaTugba
Josephine
Josephine
Josephine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
JosephineJosephine
Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
At maximum frown. Actual patient. Results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
At maximum frown. Jeuveau® patient. Individual results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Ready?
Join The Club

Only in select cities. Participating providers only.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Join the club

Only in select cities. Participating providers only.